ACTRN12620000056998尚未招募未知
A multi-centre, multi-specialty collaboration for creating a consistent valid scoring tool using patient skin field photographs for tumour severity and extent assessment of skin field cancerisation
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- GenesisCare
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- o limit 至 o limit（—）
- 性别
- All
入选标准
- •1. Treatable region of Skin Field Cancerisation in at least one of the following regional areas:
- •o Cheek (one)
- •o Ear (one)
- •o Forearm (one)
- •o Back of Hand (one)
- •o Lower leg (one)
- •o Top of foot (one)
- •o Chest (Decolletage)
- •o Torso (or front or back)
- •2. De-identified - Photographs of participants over 18 years of age. Photographs will be collected only from two sites from patients who attended clinics .These two sites are QIDerm in Brisbane and St Vincent's Hospital in Melbourne.
- •The images will have sufficient protection to protect patient privacy. Only areas that are considered inherently non-identifiable i.e., forearms, lower legs, chest and scalp are included. Any other sites will have blackouts of the eyes and other identifying features. All photos will be de-identified before being added to the study and there will be no photos with identifying tattoos or distinctive markings. This process is being used to protect the privacy of the participants and for the fact that identifiable markings will interfere with the scoring system. De-identified photography will be used in the study in accordance with the Australian Privacy Principals Guidelines Act 1988. All imaging will remove eye features and other distinguishing skin markings that could be used to identify participants. Imaging is part of standard clinical care and consent for taking these images is part of the general dermatologist’s practice consent process (Please see consent forms for the QIDerm and Dr Baker’s practice)
排除标准
- •Poor quality photographs;
- •Other dermatoses effecting assessment (e.g. inflammatory
- •skin diseases) that may confuse scorers.
研究者
相似试验
招募中
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862EUCTR2022-001837-35-LTBasilea Pharmaceutica International Ltd, Allschwil15
进行中（未招募）
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862EUCTR2022-001837-35-PLBasilea Pharmaceutica International Ltd, Allschwil15
进行中（未招募）
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-001837-35-SKBasilea Pharmaceutica International Ltd, Allschwil8
进行中（未招募）
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageEUCTR2022-001837-35-DEBasilea Pharmaceutica International Ltd, Allschwil8
招募中
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageEUCTR2022-001837-35-BGBasilea Pharmaceutica International Ltd, Allschwil8